Abstract. The present study investigated the effect of combined sorafenib chemotherapy on hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression and survival time of patients with advanced gastric cancer. From
Introduction
Advanced gastric cancer is characterized by tumors that invade the muscle layer and serosa of the stomach, regardless of lesion size and occurrence of metastasis (1) . The treatment strategy for advanced gastric cancer is primarily surgery, assisted by postoperative adjuvant chemotherapy (2) . Because of the poor targeting ability of traditional chemotherapeutic drugs, normal tissues are also damaged during inhibition of tumor metastasis. Targeted therapies are drugs that work at the molecular level, and designed according to specific carcinogenic molecules (including proteins in tumor cells or gene fragments). These drugs specifically enter tumor cells and selectively bind carcinogenic molecules and cause tumor cell death without injuring normal tissue surrounding the tumor (3) (4) (5) .
Sorafenib is a new multi-target oral drug for cancer treatment. It can be used to treat gastrointestinal stromal tumors and metastatic renal cell carcinoma for patients who are not responsive to, or cannot tolerate standard therapies (6) . It can selectively target certain proteins, so as to regulate the growth and metabolism of tumor cells. Tumor cells can proliferate under hypoxic conditions. This phenomenon is closely related to the activation of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF). HIF-1α can enhance the metabolism of cells under hypoxic conditions and contribute to activation of VEGF to induce tumor angiogenesis (7) (8) (9) .
Previous studies have found that because of the hidden incidence of gastric cancer, many patients are first diagnosed with advanced gastric cancer, or even with metastasis, and have therefore missed the optimal time for surgery (4, 10, 11) . At present, to improve the survival of patients with advanced gastric cancer, physicians apply neoadjuvant chemotherapy, which is highly effective (10) . Neoadjuvant chemotherapy is the administration of 3-4 cycles of standard chemotherapy before surgery, to reduce the tumor scope and achieve the purpose of surgical resection (11) . In the present study, we Blood collection. A total of 3 ml venous blood was collected from the elbow vein in the morning and placed in ordinary plastic tubes. A total of 1.8 ml was then transferred to anticoagulation tubes containing 0.2 ml 3.8% sodium citrate. Specimens were centrifuged at 1,000 x g for 10 min within 1 h after collection. Serum or plasma were separated and stored in 0.5 ml EP tubes after extraction, and stored at -30˚C until use within 1 month. 
Measurement of serum VEGF and HIF-1α by enzyme-linked immunosorbent assay (ELISA

Results
Comparison of general clinical conditions of patients.
We collected and analyzed the general clinical data of patients with gastric cancer in the two groups including, age, weight and course of disease. Most patients were aged from 50 to 60 years, and there were no statistically significant differences in age, body weight or course of gastric cancer among patients in the two groups (P>0.05) ( Table I) .
Measurement of serum levels of VEGF and HIF-1α before and after neoadjuvant chemotherapy. VEGF and HIF-1α expression levels in peripheral blood of patients and healthy controls were measured by ELISA. We found that compared with healthy controls, the serum levels of VEGF and HIF-1α were significantly higher in both the treatment group and the control group before neoadjuvant chemotherapy (P<0.05), and no statistical differences were found between the two groups (P>0.05). Compared with the control group, the serum levels of VEGF and HIF-1α in the treatment group were significantly lower after neoadjuvant chemotherapy (P<0.05) (Table II) .
Immunohistochemical staining of VEGF and HIF-1α.
The levels of VEGF and HIF-1α in the postoperative gastric cancer tissue of the two groups of patients were detected by immunohistochemistry. The results showed that compared with the control group, the levels of VEGF and HIF-1α in the treatment group were significantly lower ( Fig. 1) (P<0.05) .
Survival curve. The 5-year survival rate of patients in the two groups were followed. Compared with the control group, the 5-year survival rate of the treatment group was significantly higher (P<0.05) (Fig. 2) . 
Discussion
Gastric cancer has one of the highest mortality rates in cancer.
Increasing numbers of patients with advanced gastric cancer achieve good therapeutic effects because of several recent advances in treatment and the development of targeted therapeutic agents. However, because of hidden clinical symptoms, patients are usually first diagnosed with advanced gastric cancer, with poor prognosis and the median overall survival period is <12 months (12) . Therefore, prolonging survival time and improving survival rate of patients with advanced gastric cancer are key to treatment (13) . Angiogenesis is the basis of proliferation, invasion and metastasis of advanced gastric cancer. VEGF can induce the proliferation of vascular endothelial cells, promote endothelial cell survival of the newly formed vessels, and increase vascular permeability (5), which contribute to metastasis and invasion of tumor cells. Our results showed that serum levels of VEGF and HIF-1α were both significantly increased in advanced gastric cancer patients (P<0.05). These observations were consistent with previous studies (5, 14) . We believe that 5-FU combined with sorafenib can significantly reduce the expression of VEGF in gastric cancer tissue. Therefore, drugs targeting VEGF and its receptor will ideally help to suppress tumor proliferation, invasion and metastasis. In addition, a previous study illustrated that there is a phenomenon in most cancer cells known as the 'Warburg effect', which refers to tumor cells in hypoxic or anoxic conditions that can proliferate by increasing the rates of glycolysis and lactic acid fermentation (15) . The rates of glycolysis and lactic acid fermentation of tumor cells can also increase significantly under normoxic conditions. Hypoxia is a common feature of solid tumors in the middle and late stage. Hypoxia will stimulate a series of adaptive responses such as tumor angiogenesis, increased drug resistance and enhanced metastasis ability (16) . The transcription factor, HIF-1α, plays a central role in these processes. The expression of HIF-1α can increase significantly under hypoxic conditions, and it improves the cell's tolerance to hypoxia. It has therefore become a potential anticancer target as well (17) . Our study showed that in addition to the increase of serum VEGF in patients with advanced gastric cancer, HIF-1α level was also significantly higher than in healthy controls. Immunohistochemical staining of tumor tissue showed that HIF-1α level in tumor tissue was significantly increased compared with adjacent normal tissue. This demonstrates that HIF-1α overexpression occurs in advanced gastric tumor tissue. We believe that increased HIF-1α expression level can further enhance tumor tissue survival in the hypoxic environment and promote anaerobic metabolism of tumor tissue. Yu et al (18) found that in this process, the transcription factor c-Jun blocked proteasome-mediated degradation of HIF-1α and stabilized HIF-1α protein. In addition, c-Jun reduced HIF-1α ubiquitylation and increased its stability, which resulted in enhanced VEGF transcription and increased VEGF secretion by tumor cells, which promoted angiogenesis. The above results showed that c-Jun exerted a molecular barrier function by binding to the ODD domain of HIF-1α, prevented its ubiquitination and degradation, stabilized HIF-1α protein, and consequently promoted transcription and mediation of tumor angiogenesis. Sorafenib is a new oral multi-target drug for cancer treatment.
The primary goal during its development was to treat gastrointestinal stromal tumors and metastatic renal cell carcinoma for patients who are not responsive to, or cannot tolerate standard therapies. It selectively targets certain protein receptors which act as molecular switches in the process of tumor growth. Previously, drug monotherapy was commonly used for the treatment of hepatocellular carcinoma (19) , renal clear cell carcinoma (20) , and colorectal cancer (21) and good therapeutic effects were obtained. Through the evaluation of 5-year survival rate among patients in the 2 groups, we found that when chemotherapy based on sorafenib combined with 5-FU was used, the postoperative 5-year survival rate was significantly increased, thus demonstrating that this combination chemotherapy has clinical value.
In conclusion, we believe that VEGF and HIF-1α have important clinical value for the evaluation of proliferation and metastasis of advanced gastric cancer patients. When neoadjuvant chemotherapy is employed and its clinical efficacy is observed, VEGF and HIF-1α can be used as new observational indices of the efficacy of neoadjuvant chemotherapy.
